Faculty profile
Michael Hayden
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
The Lancet. Neurology · 2024
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.
The Journal of pharmacology and experimental therapeutics · 2023
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.
Autophagy · 2023
Latest funding
- $140,000
Investigation of optimal therapies for Huntington's disease using antisense oligonucleotides for huntingtin lowering and somatic instability
CIHR · 2025 · Supervisor
- $210,000
Investigation of extracellular vesicles as non-invasive biomarkers in Huntington disease
CIHR · 2024 · Supervisor
- $105,000
Determining the mechanism of action of cis-acting modifiers on the age of onset of Huntington Disease
CIHR · 2019 · Supervisor
10 publications.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF, LEGATO-HD Study Group
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.
Cutts A, Chowdhury S, Ratkay LG, Eyers M, Young C, Namdari R, Cadieux JA, Chahal N, Grimwood M, Zhang Z, Lin S, Tietjen I, Xie Z, Robinette L, Sojo L, Waldbrook M, Hayden M, Mansour T, Pimstone S, Goldberg YP, Webb M, Cohen CJ
Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine.
Wang SM, Wu HE, Yasui Y, Geva M, Hayden M, Maurice T, Cozzolino M, Su TP
Mitochondrial and redox modifications in early stages of Huntington's disease.
Lopes C, Ferreira IL, Maranga C, Beatriz M, Mota SI, Sereno J, Castelhano J, Abrunhosa A, Oliveira F, De Rosa M, Hayden M, Laço MN, Januário C, Castelo Branco M, Rego AC
Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A, Trotta CR, Narasimhan J, Wiedinger KJ, Li W, Effenberger KA, Woll MG, Jani MB, Risher N, Yeh S, Cheng Y, Sydorenko N, Moon YC, Karp GM, Weetall M, Dakka A, Gabbeta V, Naryshkin NA, Graci JD, Tripodi T, Southwell A, Hayden M, Colacino JM, Peltz SW
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M
A true mentor and pioneer in medical genetics.
Hayden M
High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice.
Rinninger F, Heine M, Singaraja R, Hayden M, Brundert M, Ramakrishnan R, Heeren J
Public perceptions of pharmacogenetics.
Zhang SC, Bruce C, Hayden M, Rieder MJ
Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y, Koutrikas G, Tassé AM, Issa A, Carleton B, Hayden M, Rieder MJ, Ramos-Paque E, Avard D
Investigation of optimal therapies for Huntington's disease using antisense oligonucleotides for huntingtin lowering and somatic instability
Principal investigators: Barron, Jessica C
Keywords: Dna Mismatch Repair; Gene Therapy; Huntington'S Disease; Mouse Models; Neurohistology; Proteomics; Somatic Expansion; Transcriptiomics
Investigation of extracellular vesicles as non-invasive biomarkers in Huntington disease
Principal investigators: Caldeira Bras, Ines Filipa
Keywords: Biofluids; Biomarkers; Extracellular Vesicles; Huntington Disease
Determining the mechanism of action of cis-acting modifiers on the age of onset of Huntington Disease
Principal investigators: Findlay Black, Hailey R
Keywords: Dna Repair; Huntington Disease; Neurodegeneration; Trinucleotide Repeat Disorders
Redevelopment and Optimization of an Adeno-Associated Virus Gene Therapy for the Treatment of Lipoprotein Lipase Deficiency
Principal investigators: Mehta, Neel
Keywords: Adeno-Associated Viral Vector; Gene Therapy; Genetic Diseases; Hypertriglyceridemia; Lipid Transport; Lipoprotein Lipase; Lipoprotein Lipase Deficiency
Targeting Post-Translational Modifications of Huntingtin to treat Huntington disease
Principal investigators: Lemarie, Fanny L
Keywords: Autophagy; Fatty Acylation; Huntingtin; Huntington Disease; Lipidation; Phosphorylation; Post-Translational Modification (Ptm); Proteolysis
Allele-specific lowering of mutant polyQ proteins as treatment for Huntington disease, spinocerebellar ataxia type 3 and spinocerebellar ataxia type 7
Principal investigators: Hayden, Michael R
Keywords: Animal Models; Antisense Oligonucleotides; Crispr/Cas9; Gene Silencing; Huntington Disease; Polyglutamine Diseases; Sca3; Sca7; Sirna
Novel Approaches Directed to Prevention and Treatment of Huntington Disease
Principal investigators: Hayden, Michael R
Keywords: Animal Models; Drug Deliveries System; Excitotoxicity; Gene Silencing; Huntington Disease; Novel Pathways; Proteolysis
Aberrant NMDA receptor and synaptic signaling in vulnerability to neurodegeneration: Focus on Huntington disease
Principal investigators: Raymond, Lynn A
Keywords: Acute Brain Slice; Electrophysiology; Huntington Disease; Neurodegeneration; Nmda Receptor; Optogenetics; Primary Neuronal Culture; Striatum; Synaptic Plasticity; Western Blot
Canada Research Chair Tier 1
Principal investigators: Hayden, Michael R
Keywords: Crc
Bioinformatic and functional approaches to cancer pharmacogenomics
Principal investigators: Wright, Galen E
Keywords: Bioinformatics; Genomics; In Vitro Validation; Personalized Medicine; Pharmacogenomics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medical Genetics
- Pediatrics
- Human Genetics
- Medicine
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.